Depomed To Present At Jefferies 2013 Global Healthcare Conference
NEWARK, Calif., May 28, 2013
NEWARK, Calif., May 28, 2013 /PRNewswire/ --Depomed, Inc. (NASDAQ: DEPO)
today announced that it will be presenting at the Jefferies 2013 Global
Healthcare Conference at the Grand Hyatt in New York City.
The presentation at the Jefferies conference is scheduled for 4:30 pm EDT
(1:30 pm PDT) on Monday, June 3, 2013. The presentation will be webcast, and
the webcast can be accessed via the Investor Relations page of the Depomed
website at www.depomed.com. A recording of the webcast will be archived for
30 days on the company's website.
Depomed, Inc.is a specialty pharmaceutical company with three approved and
marketed products. Gralise^®(gabapentin) is a once-daily treatment approved
for the management of postherpetic neuralgia (PHN). Zipsor^®(diclofenac
potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug
(NSAID) indicated for relief of mild to moderate acute pain in adults.
Glumetza^®(metformin hydrochloride extended release tablets) is approved for
use in adults with type 2 diabetes and is commercialized bySantarus,
Inc.inthe United States. The company formulates its products and product
candidates with its proven, proprietary Acuform^®drug delivery technology,
which is designed to improve existing oral medications, allowing for extended
release of medications to the upper gastrointestinal tract when dosed with
food. Additional information aboutDepomedmay be found on its
August J. Moretti
SOURCE Depomed, Inc.
Press spacebar to pause and continue. Press esc to stop.